Rhabdomyolysis Following Administration of Comirnaty®
  • Catarina Elias
    Serviço de Medicina Interna, Centro Hospitalar Universitário São João, Porto, Portugal
  • Pedro Cardoso
    Serviço de Gastrenterologia, Centro Hospitalar Universitário São João, Porto, Portugal
  • Diana Gonçalves
    Thoracic Surgery Department, Centro Hospitalar e Universitário de Coimbra, Portugal
  • Inês Vaz
    Unidade de Farmacovigilância do Porto, Faculdade de Medicina da Universidade do Porto, Porto, Portugal
  • Leila Cardoso
    Serviço de Medicina Interna, Centro Hospitalar Universitário São João, Porto, Portugal


Rhabdomyolysis, vaccination, COVID-19, Comirnaty


Introduction: Vaccination against COVID-19 is essential to control the pandemic. The vaccines developed so far have good safety profiles but full knowledge of adverse effects will only be acquired with time and through case reports.

Case Description: We present the case of a man admitted with rhabdomyolysis 3 days after receiving his first dose of the Pfizer coronavirus vaccine Comirnaty® Other traumatic, infectious, endocrine, electrolyte disturbance and autoimmune causes of rhabdomyolysis were excluded. The temporal relationship between vaccine administration and disease onset indicated possible causality. The patient had a favourable evolution after receiving fluids and completely recovered. To our knowledge, there have been only 69 reports of rhabdomyolysis following Comirnaty® administration in Europe, as stated by the European Medicines Agency, and this is the first case report in Portugal.

Discussion: When a patient presents with rhabdomyolysis without an obvious traumatic or exertional cause, other aetiologies need to be excluded. Drug use is one of the most common causes of rhabdomyolysis in adults.

Conclusion: We present a case compatible with an adverse effect of Comirnaty® in order to raise awareness of this condition in vaccinated patients.




  • Torres PA, Helmstetter JA, Kaye AM, Kaye AD. Rhabdomyolysis: pathogenesis, diagnosis, and treatment. Ochsner J 2015;15:58–69.
  • Nance JR, Mammen AL. Diagnostic evaluation of rhabdomyolysis. Muscle Nerve 2015;51:793–810.
  • Nassar M, Chung H, Dhayaparan Y, Nyein A, Acevedo BJ, Chicos C, et al. COVID-19 vaccine induced rhabdomyolysis: case report with literature review. Diabetes Metab Syndr 2021;15:102170.
  • European Medicines Agency. Comirnaty: EPAR – Product Information [Internet]. 2021. https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf (accessed 20 July 2021).
  • Views: 590
    HTML downloads: 90
    PDF downloads: 268

    Published: 2021-08-30
    Issue: 2021: Vol 8 No 8 (view)

    How to cite:
    Elias C, Cardoso P, Gonçalves D, Vaz I, Cardoso L. Rhabdomyolysis Following Administration of Comirnaty®. EJCRIM 2021;8 doi:10.12890/2021_002796.

    Most read articles by the same author(s)